Nectar Lifesciences Limited (NSE:NECLIFE)

Market Cap	2.60B -68.3%
Revenue (ttm)	16.70B -0.7%
Net Income	-3.55B
EPS	-15.86
Shares Out	194.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,351
Average Volume	317,383
Open	13.61
Previous Close	13.40
Day's Range	13.20 - 13.61
52-Week Range	13.05 - 33.18
Beta	0.33
RSI	32.47
Earnings Date	Jan 23, 2026

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufa...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,786
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NECLIFE